Biologic Drugs and Biosimilars

The video discusses biologic drugs, highlighting their differences from small molecule drugs. It explains the complex manufacturing process of biologics, their mechanisms in treating diseases, and the challenges in creating biosimilars. Despite being effective, biosimilars face high production costs and regulatory hurdles. The video also covers the market and legal aspects influencing biosimilar availability, particularly in the U.S. compared to Europe.

What are the implications of the cost differences between small molecule drugs and biologics?

What are the regulatory differences between generic drugs and biosimilars?

Why was there a delay in the approval of biosimilars in the United States compared to Europe?